Hemispherx BioPharma (NYSE American:HEB) CEO Thomas Equels tells Proactive Investors that the biopharma has made significant progress in the study of its flagship drug Ampligen in treating ovarian cancer.
Equels is presenting at the Planet MicroCap Showcase today, in Las Vegas. A live webcast of the presentation can be viewed here:
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE